



NDA 211746/S-002

SUPPLEMENT APPROVAL

Glenmark Specialty SA
c/o Glenmark Pharmaceuticals Inc., USA
Attention: Thomas Callaghan
Director, Regulatory Affairs, USA
750 Corporate Drive
Mahwah, NJ 07430

Dear Mr. Callaghan:

Please refer to your Supplemental New Drug Application (sNDA) dated and received April 1, 2022, and your amendment, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Ryaltris (olopatadine hydrochloride and mometasone furoate monohydrate nasal spray).

This “Changes Being Effected” supplemental new drug application provides for changes to the carton labeling to include Instruction for Use (IFU) statement to both commercial and professional sample presentations.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CARTON AND CONTAINER LABELS

Submit final printed carton and container labels that are identical to enclosed carton and container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 211746/S-002.**” Approval of this submission by FDA is not required before the labeling is used.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Teicher Agosto, Regulatory Business Process Manager, at (240) 402 - 3777.

Sincerely,

{See appended electronic signature page}

Ramesh Raghavachari, Ph.D.
Chief, Branch I
Division of Post-Marketing Activities I
Office of Lifecycle Drug Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure(s):

Carton and Container Labeling



Ramesh
Raghavachari

Digitally signed by Ramesh Raghavachari
Date: 9/30/2022 11:27:52PM
GUID: 502d0913000029f375128b0de8c50020